Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, ...
Le Lézard

St. Joseph's at Fleming Selects LGI Workforce Pro to Modernize Long-Term Care Workforce Management

LGI Healthcare Solutions, a Canadian leader in healthcare IT, is pleased to announce that St. Joseph's at Fleming, a ...
Le Lézard

10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling

Genomics, Inc. , a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to ...